首页> 美国卫生研究院文献>Journal of Basic and Clinical Pharmacy >Acute pancreatitis in the use of canagliflozin: A rare side-effect of the novel therapy for type 2 diabetes mellitus
【2h】

Acute pancreatitis in the use of canagliflozin: A rare side-effect of the novel therapy for type 2 diabetes mellitus

机译:卡那列净使用中的急性胰腺炎:这种新型疗法治疗2型糖尿病的罕见副作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Canagliflozin (Invokana) is an innovative treatment for type 2 diabetes mellitus (DM) approved in a new class acknowledged as sodium-glucose co-transporter 2 inhibitors. Acute pancreatitis is a very rare side effect with an incidence <1%. a 50-year-old white male with DM type 2 presented to the emergency department with acute onset of abdominal pain after 4 days treatment with canagliflozin. He was successfully diagnosed with diabetic ketoacidosis induced by acute pancreatitis. Canagliflozin was discontinued. His diabetic ketoacidosis was improved after aggressive intravenous fluid along with intravenous insulin infusion. Our case demonstrates very rare but serious side effect, acute pancreatitis in the use of canagliflozin. As the utility of canagliflozin expands, physicians must be aware of this potentially fatal adverse effect. More specific details on potential candidates for this novel therapy are urgently needed.
机译:Canagliflozin(Invokana)是一种创新的2型糖尿病(DM)治疗药物,被批准为一类公认的钠葡萄糖共转运蛋白2抑制剂。急性胰腺炎是一种非常罕见的副作用,其发生率<1%。接受卡格列净治疗4天后,一位50岁的2型DM白人男性出现急症,出现腹痛。他被成功诊断出患有急性胰腺炎引起的糖尿病性酮症酸中毒。 Canagliflozin已停药。积极的静脉输液和静脉注射胰岛素后,他的糖尿病酮症酸中毒得到了改善。我们的病例显示,使用卡格列净治疗非常罕见但严重的副作用是急性胰腺炎。随着canagliflozin的用途扩展,医生必须意识到这种潜在的致命不良作用。迫切需要有关这种新型疗法的潜在候选药物的更多具体细节。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号